about
Vaccine protection against Zika virus from BrazilZika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus MonkeysMosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric viromeRapid development of a DNA vaccine for Zika virusConstruction and evaluation of novel rhesus monkey adenovirus vaccine vectors.Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humansInternational seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsVaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysComparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and DProduction of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env SequencesAttenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by VectorizationAdenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys.Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function.Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.Vaccine delivery with microneedle skin patches in nonhuman primates.Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.Therapeutic efficacy of vectored PGT121 gene delivery in HIV-1-infected humanized mice.Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys.
P50
Q25165129-98D7B9C4-9D6D-439D-917A-619F18B051E5Q29587262-C9B9095A-1948-4302-B2C2-1A014E6B82CFQ33712578-63DA4DBA-9FD2-4B93-A909-E9188212F598Q33780980-FC155D6A-DC1A-46BD-BB0D-469CCBE3CE2CQ34120780-46AFA5AF-B5EC-44C1-8C6A-4603730108D6Q34209026-1842ADF0-F268-4BAA-86BE-BD298D694566Q34305895-CBBAA4DE-CFA4-410E-8ECA-8974E5B76B31Q34542032-0FD079D1-8050-4821-9049-8D0A0B30EC84Q34991437-8D48657E-C262-4536-B48E-0A904EF983C3Q35055188-59F1B5A0-847A-40F3-9183-AFB2B9982035Q35112755-B6436196-E303-41AA-A286-9DC896B0C407Q35729899-943D64F5-238D-4469-B423-2311B039668FQ35857420-7CC59396-5C29-4934-80B8-4DADA9930DA2Q35915764-31159512-CE88-489B-88DF-50442B5F9F94Q36211653-33D6322B-42E4-44E7-9A71-88F5A08CBCE9Q36276518-82EABF7B-C672-498C-A200-2716576AE755Q36300153-07B3852A-A466-4D5A-8CD5-8D38AB7287D9Q36495581-3512CB73-187D-4AE0-9D4B-401B137E3141Q36495587-460B3673-9F92-4045-8F3D-5269CD9262C5Q37333924-CED561BC-2AED-4DAD-A7FF-E739E69AF50EQ37355237-E300537A-681B-4E1D-8032-A49780F376DFQ37486401-A608716D-636B-4650-A714-3370AF2BDBEFQ37586965-9C854EF2-8E9E-40C4-93C7-521552712874Q37661779-A58953C6-FCFC-4C15-A733-81A0DE2FF0C7Q38157106-697BA9C1-B54D-4EDA-B752-253D984541B0Q38480709-5F1CDEBB-8772-4314-BAC8-A1A1ED9AA1CEQ38645979-1B5C0FFC-B52F-4E80-A4CB-5D154179B1F8Q39266707-C53EEBF3-8752-4E6B-BBF4-D52C0C368CB8Q39612726-E0540303-3ACE-403E-AC28-EEA96053BEFCQ40055103-85FF79B5-BA3F-419C-9F64-EE8B3519C280Q40187584-1736C590-2183-42D7-A594-3B52597E1B9DQ41933482-7A7A9795-5459-4189-9A64-83A180DC0164Q43183487-A03EEF98-E688-455B-844A-E87C8DEBE228Q43212235-C37C9112-6C35-42DB-99C2-22A92FF69620Q45323630-EB1362A8-C06A-4DC1-B5B4-AC80A3C002AFQ45857523-56D9D1B8-7ABE-4F38-A624-AAC1154D8A14Q47315490-24A8F386-9947-4886-BA40-415352C79068Q47555891-E3DA3804-D5CB-4A80-A826-44461CD9F4EAQ47558367-28A1AACC-CE31-41BE-8B11-CE5431608D7EQ51335899-35C1FE0A-2B5E-41C5-A199-78EC9D9299E5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter Abbink
@ast
Peter Abbink
@en
Peter Abbink
@es
Peter Abbink
@nl
Peter Abbink
@sl
type
label
Peter Abbink
@ast
Peter Abbink
@en
Peter Abbink
@es
Peter Abbink
@nl
Peter Abbink
@sl
prefLabel
Peter Abbink
@ast
Peter Abbink
@en
Peter Abbink
@es
Peter Abbink
@nl
Peter Abbink
@sl
P106
P21
P31
P496
0000-0003-1978-088X